NCT02512757 is a clinical trial in Lung Cancer, sponsored by Innovis LLC.

Who is sponsoring NCT02512757?

NCT02512757 is sponsored by Innovis LLC.

What condition does NCT02512757 study?

NCT02512757 studies Lung Cancer.

Is NCT02512757 still recruiting?

NCT02512757 is currently completed. Last updated 28 February 2018.

Last reviewed 2018-02-28 · How we verify

NCT02512757

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology

Completed Last updated 28 February 2018

What this trial tests

trial in Lung Cancer in 150 participants. Completed in 17 July 2017.

Timeline

13 August 2015

Primary endpoint
17 July 2017

17 July 2017

Quick facts

Lead sponsor	Innovis LLC
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150
Start date	13 August 2015
Primary completion	17 July 2017
Estimated completion	17 July 2017
Sites	3 locations across United States

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Innovis LLC

Who can join

Adults 18 to 79, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Innovis LLC trials

Trials by the same sponsor.

NCT06294886 — Vaginal Fluid Collection for Detection of Endometrial Cancer · unknown
NCT06294873 — Stool Sample Collection Study · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02512757 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innovis LLC
Last refreshed: 28 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02512757.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing